European Pharmacovigilance & Clinical Trials 2016

Top Quote Our conferences gives an unique opportunity for knowledge exchange and discussions in a very professional setting. Experience a peer-to-peer connection and knowledge sharing through our exclusive networking opportunities that leads to innovation and collaboration. End Quote
  • (1888PressRelease) July 02, 2016 - The European Pharmacovigilance & Clinical Trials 2016 offers a one of a kind discussion platform for pharmaceutical experts to debate and discuss the challenges they are facing in Pharmacovigilance and Clinical Trials.

    Do not miss out on the chance to acquire first-hand knowledge and experiences from pharmaceutical giants such as AstraZeneca, Merck Sereno, Boehringer Ingelheim, Pfizer, Novo Nordisk, Johnson & Johnson, Novartis and many more on the latest technological advances in data capture and effective feasibility models. We will be addressing topics such as Major challenges faced by EU legislation and Emerging Economies and PV Harmonization, Adverse event reporting and PV & clinical trials, Clinical Trials Signal Detection and many others. Join us and be future ready!

    Take advantage to meet the leading experts within the field and discuss the latest challenges all your competitors are facing.
    We are looking forward to welcoming you on board in 2016!

    KEY HIGHLIGHTS:
    Harmonization and Pharmacovigilance
    PV regulations and challenges
    The new EU legislation on clinical trials, its impact and future
    Risk management and minimization
    Adverse drug reactions reporting
    Signal detection and post authorization safety
    Business development and models in clinical trials
    Clinical data management
    Good Clinical Practices and Good Pharmacovigilance practices
    IT and new technologies for improvement of PV and clinical research
    Strategies to improve clinical trials and PV

    KEY SPEAKER:
    Karen Cheng Heil, Safety Medical Director, AstraZeneca
    Shelagh Anderson, Vice President of Global Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson
    Ana-Claudia Ianos, Director - Safety Risk Lead, Pfizer
    Emanuel Lohrmann, Lead Safety Physician, Boehringer Ingelheim
    Heike Schoepper, Head Global Drug Safety, Merck Serono
    Kashif Sheikh, Senior Safety Surveillance Advisor, Novo Nordisk
    Alexandru Ionel, Chief Scientific Officer & DRA Head, Novartis Pharma
    Julia Appelskog, QPPV, Head of Pharmacovigilance, Bluefish Pharmaceuticals
    Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting
    Jonathan Seltzer, President, ACI Clinical
    Anne Gramkow, Head of Safety and QPPV, Pharmacosmos
    Leo Ayerakwa, Consultant, European Regulatory Solutions
    Nawab Qizilbash, Head & Honorary Senior Lecturer in Pharmacoepidemiology, OXON Epidemiology
    Simon Ingate, Principal Consultant - SafetyGauge Product Manager, Pope Woodhead & Associates
    Rachel Spokes, Vice President of Pharmacovigilance, EmasPharma

    WHO SHOULD ATTEND THE CONFERENCE:
    CEO's, CTO's, CIO's, Presidents, Vice Presidents, Directors, Heads & Managers, Scientific Advisors, Consultants and professionals from pharmaceutical and biotechnology industries, CROs and service providers involved in Pharmacovigilance or Clinical Trials. Attendees' job responsibilities include:
    Pharmacovigilance
    Safety & Risk management
    Drug safety
    QPPV
    PV Compliance
    PSMF
    Safety Surveillance
    Medical Affairs
    Signal detection
    Regulatory Affairs
    Inspection and Audit
    Pharmacoepidemiology
    Clinical Operations
    Clinical Research and Development
    Clinical Quality Assurance/Control
    Clinical Compliance
    GCP
    Clinical Monitoring
    Clinical Data Management
    Contract outsourcing service providers
    IT consultants

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information